What does the evidence say about Myo-Inositol Metabolic Syndrome Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Myo-Inositol Metabolic Syndrome Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - The term polycystic ovary syndrome (PCOS) has traditionally been used in international evidence-based guidelines, including the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS []. [Yanachkova Vesselina (2026); evidence level 3] - In addition, disorders in insulin signaling have a significant impact on glucose metabolism, adipose tissue, and energy balance, which determines the increased risk of metabolic complications in these patients [,,,]. [Yanachkova Vesselina (2026); evidence level 3] - In this regard, metabolic risk assessment should be an integral part of the diagnostic process in all patients with PCOS regardless of their phenotype. [Yanachkova Vesselina (2026); evidence level 3] - 1 2 3 4 Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age, with a prevalence ranging from 6% to 20%, depending on the diagnostic criteria applied. [Yanachkova Vesselina (2026); evidence level 3] - 1 2 The quest for the best strategy to apply in cases of overweight, obesity, metabolic alterations, and increased cardiovascular risk has challenged scientists for decades. [Ricottini Lucilla (2024); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.